Contraindications to Restarting Antiplatelets After Ischemic Stroke
In a 44-year-old patient with prior embolic ischemic stroke, the primary absolute contraindication to restarting antiplatelet therapy is a history of intracerebral hemorrhage (ICH), particularly if the patient has not been on antithrombotic therapy previously or has high-risk imaging features such as lobar ICH or cerebral amyloid angiopathy. 1, 2
Key Disease Processes That Contraindicate Antiplatelet Resumption
Absolute/Strong Contraindications
- Active intracerebral hemorrhage - particularly within the first 24 hours of ICH onset 2
- ICH secondary to structural causes including:
- Aneurysm
- Arteriovenous malformation
- Cavernoma
- Venous thrombosis
- Tumor 1
- Hemorrhagic transformation of cerebral infarction 1
- Active gastrointestinal bleeding 3
- Severe uncontrolled bleeding diathesis
Relative Contraindications Requiring Careful Risk-Benefit Assessment
- History of ICH associated with prior antiplatelet use - though recent evidence suggests this may not be absolute 1, 2
- Lobar ICH with imaging biomarkers of cerebral amyloid angiopathy - these patients have highest recurrent ICH risk 1
- Severe renal dysfunction - significantly increases re-bleeding risk (HR 4.631) 4
- Recurrent falls or poor compliance 3
- Uncontrolled epilepsy 3
Clinical Decision Algorithm
Step 1: Exclude Absolute Contraindications
- Recent ICH (especially <24 hours)
- Structural vascular lesions causing hemorrhage
- Active bleeding
Step 2: Assess Thrombotic Risk
High thrombotic risk favoring antiplatelet resumption:
- Mechanical heart valve or LVAD 2
- Recent myocardial infarction
- Atrial fibrillation (though anticoagulation may be preferred) 2
- Multiple prior ischemic strokes
- High-risk cardiac conditions 3, 5
Step 3: Assess Hemorrhagic Risk
High hemorrhagic risk arguing against resumption:
- Lobar ICH location
- Cerebral amyloid angiopathy on imaging
- Multiple cerebral microbleeds
- Severe renal dysfunction 4
- Asian ethnicity (higher ICH recurrence risk with antiplatelets) 6
Step 4: Timing Considerations
If restarting antiplatelets after ICH:
- Wait ≥24 hours minimum after ICH symptom onset 1
- Optimal timing: 7-8 weeks after ICH for anticoagulation 2
- Earlier resumption (median 76 days) showed safety in RESTART trial 1
Important Evidence-Based Nuances
For patients with prior ICH: The RESTART trial (2023) showed that restarting antiplatelet therapy after ICH was not associated with increased recurrent ICH risk (adjusted HR 0.51,95% CI 0.25-1.03) and may actually reduce major adverse cardiovascular events 1. However, current guidelines rate this as Level B evidence, indicating moderate certainty 1, 2.
Racial/ethnic considerations: Asian populations show significantly higher ICH recurrence risk with antiplatelet resumption (OR 1.48) compared to Caucasians (OR 0.85), requiring more cautious approach 6.
For embolic ischemic stroke specifically: Since your patient had an embolic stroke, the primary concern is preventing recurrent cardioembolic events. If the embolic source is cardiac (atrial fibrillation, mechanical valve), anticoagulation rather than antiplatelet therapy is typically indicated 2, 3. Antiplatelets are generally reserved for non-cardioembolic ischemic stroke 7.
Common Pitfalls to Avoid
Don't assume all ICH history is equal - ICH associated with prior antithrombotic use may actually be safer for antiplatelet resumption than spontaneous ICH 1
Don't restart antiplatelets for cardioembolic stroke - these patients need anticoagulation assessment, not antiplatelets 2, 3
Don't ignore renal function - this is the strongest predictor of ICH recurrence (HR 4.631) 4
Don't combine aspirin + clopidogrel routinely - dual antiplatelet therapy increases bleeding without clear benefit in secondary stroke prevention 7
Don't restart immediately after any ICH - minimum 24-hour wait, preferably longer based on risk stratification 1, 2